Current progress of adeno-associated-virus-based therapy for the treatment of cystic fibrosis in humans
Nirenberg W. Will Society Be Prepared? 1966: Research
Corporation for Science Advancement. Research Corporation
Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy
in peripheral blood lymphocytes and bone marrow for
ADA-immunodeficient patients. Science 1995;270:470–75.
Sibbald B. Death but one unintended consequence of
gene-therapy trial. CMAJ 2001;164:1612.
Kim WO. Institutional review board (IRB) and ethical issues
in clinical research. Korean J Anesth 2012;62:3–12.
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of
AAV serotypes 1-9 mediated gene expression and tropism in
mice after systemic injection. Mol Ther 2008;16:1073–1080.
Schultz BR, Chamberlain JS. Recombinant adeno-associated
virus transduction and integration. Mol Ther 2008;16:
Moss RB, Milla C, Colombo J, et al. Repeated aerosolized
AAV-CFTR for treatment of cystic fibrosis: a randomized
placebo-controlled phase 2B trial. Hum Gene Ther 2007;18:
Flotte T, Carter B, Conrad C, et al. A phase I study of an
adeno-associated virus-CFTR gene vector in adult CF patients
with mild lung disease. Hum Gene Ther 1996;7:1145–1159.
Loring HS, ElMallah MK, Flotte TR. Development of rAAV2-
CFTR: History of the First rAAV Vector Product to be Used
in Humans. Hum Gene Ther Methods 2016;27:49–58.
Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB.
Correlation between DNA transfer and cystic fibrosis airway epithelial
cell correction after recombinant adeno-associated virus
serotype 2 gene therapy. Hum Gene Ther 2005;16:921–928.
Moss RB, Rodman D, Spencer LT, et al. Repeated adenoassociated
virus serotype 2 aerosol-mediated cystic fibrosis
transmembrane regulator gene transfer to the lungs of
patients with cystic fibrosis: a multicenter, double-blind,
placebo-controlled trial. Chest 2004;125:509–521.
FDA. Approved Cellular and Gene Therapy Products. 2018.
- There are currently no refbacks.